Get the Daily Brief
Latest Biotech News
Regulatory-backed cell therapy momentum
Two companies are positioning for public-market scrutiny as investors hunt for the next wave of platform-driven biotech. Aspen Neuroscience and Bambusa Therapeutics have filed for IPOs, following...
Immunology IPO deal flow accelerates
TRex Bio, backed by Eli Lilly and Johnson & Johnson in partnerships, priced an IPO to fund regulatory T-cell activation programs aimed at immune imbalance disorders. Separately, Retension...
Oncology and diagnostic imaging—new tools forecast outcomes
Spectral CT and MRI radiomics are moving from retrospective pattern-finding toward decision-support use cases. A study combining baseline dual-layer spectral detector CT features with clinical...
Clinical trial readouts—hot flashes safety and efficacy signal
Elinzanetant produced a reassuring safety profile in a pooled analysis of four randomized trials, with no liver toxicity or cancer signals reported across 52 weeks. The study also described mostly...
Drug discovery science—RNA chemical tags and ferroptosis escape
Mechanistic oncology research points to RNA modification as both a driver of tumor survival and a potential lever for therapy. A study found that the m6A reader protein YTHDF2 promotes melanoma...
Infectious disease epidemiology—C. difficile spread is mostly silent
A computational modeling study in hospital cancer wards overturns a common assumption about Clostridioides difficile transmission. Using six months of intensive surveillance and a model of two...
AI in diagnostics—risk stratification from routine imaging
Automated imaging analytics continue to move toward near-real-time clinical scoring. A deep learning system segmented carotid plaques on multi-contrast MRI and classified vulnerability in under a...
Immunotherapy toxicity—neurotoxicity risk tied to immune signatures
A large analysis in melanoma patients treated with immune checkpoint inhibitors identified meaningful rates of nerve damage and suggested which patients may be at higher risk. The study reported...
Clinical operations and infection control—venous line infection burden
Central line bloodstream infections in pediatrics remain a high-lethality threat. A four-year Iranian cohort study reported that 25.2% of hospitalized children with central venous catheters...
Pharma pipeline/regulatory landscape—adjuvant strategy primes respiratory immunity
A new pre-pathogen strategy aims to bridge the gap before specific respiratory vaccines are available. Researchers reported in Science Advances that the K3-SPG vaccine adjuvant temporarily primes...
FDA approval – immuno-oncology in colorectal cancer
The FDA approved atezolizumab plus chemotherapy for adjuvant treatment of stage III dMMR colon cancer after the ATOMIC phase III trial reduced the risk of recurrence or death by 50%. The decision...
IPO momentum in cell therapy – Aspen and Bambusa launch path
Aspen Neuroscience, a Gilead-backed cell therapy company, and Bambusa Therapeutics, an I&I biotech spun out of BioNTech veterans, have filed for IPOs as the market remains receptive to...
Early clinical signal and safety in immune modulation – TRex Bio IPO
TRex Bio priced an initial public offering to raise $117 million as it advances immune-regulatory programs designed to activate regulatory T cells. The company’s lead investigational fusion...
Drug outcome trial – stroke subtype fails to beat standard antiplatelet
A multicenter Phase III trial found that intravenous tirofiban did not outperform standard oral antiplatelet therapy for 90-day functional outcomes in acute branch atheromatous disease-related...
Precision imaging biomarkers – spectral CT predicts lymphoma treatment failure
A new study reports that baseline dual-layer spectral detector CT measurements combined with clinical factors—such as B symptoms and Ki-67—can predict which lymphoma patients will progress first...
Cell/gene editing – living patient tumor models for Duchenne
Researchers converted Duchenne patient stem-cell teratomas into humanized model systems that serve as “living test beds” for gene editing approaches. In these models, both gene-corrected cell...
Clinical trial and guideline shift – hormone therapy first-line for hot flashes
The American College of Physicians updated guidance recommending estrogen-based hormone therapy as first-line treatment for menopausal hot flashes and night sweats. The guideline also positions...
AI in cardiology – routine ECG flags coronary disease risk
A prospective study found that an AI-enhanced 12-lead ECG score accurately identified angiographically significant coronary artery disease in patients undergoing elective angiography. The results...
Sepsis and device infection burden – central line bloodstream infections
A four-year Iranian cohort study reported that bloodstream infections affected 25.2% of hospitalized children with central venous catheters, with 22.0% mortality among infected cases....
Drug delivery platform – vesicles that sense hydrostatic pressure
Researchers developed programmable nanovesicles that convert hydrostatic pressure changes into fluorescence signals by tuning membrane stiffness via pyrene-modified polyionic complex vesicles. The...